Ian Smith
Chief Medical Officer Artios Pharma
Seminars
Thursday 29th January 2026
Harnessing ATR Inhibition With Low-Dose Chemotherapy to Deliver Durable Responses in ATM-Deficient Tumors
11:30 am
• Sharing preclinical and translational data on ATR inhibition in ATM-deficient cancers
• Presenting clinical results from Phase I showing strong efficacy, including a 50% objective response rate
• Highlighting the differentiated strategy of combining ATR inhibition with low-dose chemotherapy to overcome past limitations of monotherapy
• Showcasing patient vignettes and narratives to illustrate real-world impact and translational success
